Skip to main content
SpringerLink
Log in

Once-daily atazanavir/ritonavir for HIV-associated lipodystrophy

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Moyle G, Girard J-M, Andrade J, Salvato P, Bogner J, Hay P, Santos I, Astier L, Pans M, Biguenet S, Antinori A, REAL Study Group.Continuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48 week primary analysis of the 96 week multicenter, open-label, randomized, prospective ReAL study. 17th International AIDS Conference: abstr. MOPDB103, 3 Aug 2008. Available from: URL: http://www.aids2008.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Once-daily atazanavir/ritonavir for HIV-associated lipodystrophy. React. Wkly. 1216, 4 (2008). https://doi.org/10.2165/00128415-200812160-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200812160-00008

Keywords

Search

Navigation